Results 41 to 50 of about 5,871,156 (346)
Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer
Nature, 2017 The mutant form of the GTPase KRAS is a key driver of pancreatic cancer but remains a challenging therapeutic target. Exosomes are extracellular vesicles generated by all cells, and are naturally present in the blood. Here we show that enhanced retention
S. Kamerkar +8 more
semanticscholar +1 more source
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
Journal of Hematology & Oncology, 2018 A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However,
Yiyin Zhang +11 more
doaj +1 more source
Molecular Cancer, 2021 Background Extensive studies have demonstrated the pivotal roles of circular RNAs (circRNAs) in the occurrence and development of different human cancers. However, the expression and regulatory roles of circRNAs in pancreatic ductal adenocarcinoma (PDAC)
Zeyin Rong +10 more
doaj +1 more source
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Molecular Cancer, 2020 Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising ...
Heng Zhu +10 more
doaj +1 more source
Targeting apoptosis signaling in pancreatic cancer [PDF]
, 2011 The ability to escape apoptosis or programmed cell death is a hallmark of human cancers, for example pancreatic cancer. This can promote tumorigenesis, since too little cell death by apoptosis disturbs tissue homeostasis.
Fulda, Simone
core +2 more sources
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
World Journal of Oncology, 2019 Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be ...
Prashanth Rawla, T. Sunkara, V. Gaduputi
semanticscholar +1 more source
European Journal of Cancer, 2021 INTRODUCTION Neoadjuvant therapy may improve survival compared with upfront surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality evidence is lacking.
J. V. van Dam +9 more
semanticscholar +1 more source
Role of Fibroblast Growth Factor Receptor 2 in Pancreatic Cancer: Potential Target for New Therapeutic Approach? [PDF]
, 2015 Fibroblast growth factors and their receptors play a key role in cell proliferation, migration and differentiation. Fibroblast growth factor receptor 2 (FGFR2) is involved in carcinogenesis and its altered expression has been shown in several tumors ...
Angeloni, Antonio +2 more
core +1 more source
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
New England Journal of Medicine, 2019 BACKGROUND Patients with a germline BRCA1 or BRCA2 mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population ...
T. Golan +18 more
semanticscholar +1 more source
Annual Review of Pathology: Mechanisms of Disease, 2007 The past two decades have witnessed an explosion in our understanding of pancreatic cancer, and it is now clear that pancreatic cancer is a disease of inherited (germ-line) and somatic gene mutations. The genes mutated in pancreatic cancer include KRAS2, p16/CDKN2A, TP53, and SMAD4/DPC4, and these are accompanied by a substantial compendium of genomic ...
Anirban, Maitra, Ralph H, Hruban
openaire +2 more sources